Amanda Marie Martínez
· Assistant ProfessorUniversity of North Carolina at Chapel Hill · American Studies
Active 2002–2024
About
Amanda Marie Martínez is a historian, writer, and teacher who currently serves as an Assistant Professor of American Studies at the University of North Carolina at Chapel Hill. She grew up in Santa Cruz, California, and holds a BA in History from the University of California, Berkeley, as well as a PhD in History from the University of California, Los Angeles. Her research interests focus on the intersection of race, capitalism, and popular culture. Martínez is working on a book titled "From Hillbilly to Housewife: The Evolution of the Imagined Country Music Listener," which is under contract with UNC Press. The book explores the history of the country music industry in the post-1968 era, analyzing how the genre's class mobility transformed its social and political impact, especially in relation to market success, anti-Blackness, and cultural positioning. Her work examines how country music became a tool of white grievance and how it was shaped by and contributed to racial and political dynamics from the late 1960s through the early 2000s, including the rise of Charley Pride and the post-Rodney King era. Martínez's writing has appeared in various publications such as California History, the Journal of Popular Music Studies, NPR, the Los Angeles Times, and the Washington Post. She has been a postdoctoral fellow at the James Weldon Johnson Institute for the Study of Race & Difference at Emory University, a Diversity Dissertation Fellow at Middle Tennessee State University, and a Doris G. Quinn Foundation Fellow. She has also guest edited a special issue of Southern Cultures on "Country Music's Mythology" and maintains an active profile on Google Scholar.
Research signals
Five dimensions sourced from public faculty / publication signals. Sign in to compare against your own profile and see your match score.
Research topics
- Internal medicine
- Medicine
- Virology
- Immunology
- Pediatrics
- Biology
Selected publications
MMWR Morbidity and Mortality Weekly Report · 2022 · 182 citations
- Medicine
- Pediatrics
- Internal medicine
prospective cohort of 1,364 children and adolescents aged 5-15 years was tested weekly for SARS-CoV-2, irrespective of symptoms, and upon COVID-19-associated illness during July 25, 2021-February 12, 2022. Among unvaccinated participants (i.e., those who had received no COVID-19 vaccine doses) with any laboratory-confirmed SARS-CoV-2 infection, those with B.1.617.2 (Delta) variant infections were more likely to report COVID-19 symptoms (66%) than were those with Omicron infections (49%). Among fully vaccinated children aged 5-11 years, VE against any symptomatic and asymptomatic Omicron infection 14-82 days (the longest interval after dose 2 in this age group) after receipt of dose 2 of the Pfizer-BioNTech vaccine was 31% (95% CI = 9%-48%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. Among adolescents aged 12-15 years, adjusted VE 14-149 days after dose 2 was 87% (95% CI = 49%-97%) against symptomatic and asymptomatic Delta infection and 59% (95% CI = 22%-79%) against Omicron infection. Fully vaccinated participants with Omicron infection spent an average of one half day less sick in bed than did unvaccinated participants with Omicron infection. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
New England Journal of Medicine · 2021 · 522 citations
- Virology
- Medicine
- Biology
BACKGROUND: Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in attenuating coronavirus disease 2019 (Covid-19) when administered in real-world conditions. METHODS: We conducted a prospective cohort study involving 3975 health care personnel, first responders, and other essential and frontline workers. From December 14, 2020, to April 10, 2021, the participants completed weekly SARS-CoV-2 testing by providing mid-turbinate nasal swabs for qualitative and quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) analysis. The formula for calculating vaccine effectiveness was 100% × (1 - hazard ratio for SARS-CoV-2 infection in vaccinated vs. unvaccinated participants), with adjustments for the propensity to be vaccinated, study site, occupation, and local viral circulation. RESULTS: SARS-CoV-2 was detected in 204 participants (5%), of whom 5 were fully vaccinated (≥14 days after dose 2), 11 partially vaccinated (≥14 days after dose 1 and <14 days after dose 2), and 156 unvaccinated; the 32 participants with indeterminate vaccination status (<14 days after dose 1) were excluded. Adjusted vaccine effectiveness was 91% (95% confidence interval [CI], 76 to 97) with full vaccination and 81% (95% CI, 64 to 90) with partial vaccination. Among participants with SARS-CoV-2 infection, the mean viral RNA load was 40% lower (95% CI, 16 to 57) in partially or fully vaccinated participants than in unvaccinated participants. In addition, the risk of febrile symptoms was 58% lower (relative risk, 0.42; 95% CI, 0.18 to 0.98) and the duration of illness was shorter, with 2.3 fewer days spent sick in bed (95% CI, 0.8 to 3.7). CONCLUSIONS: Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infection when administered in real-world conditions, and the vaccines attenuated the viral RNA load, risk of febrile symptoms, and duration of illness among those who had breakthrough infection despite vaccination. (Funded by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention.).
MMWR Morbidity and Mortality Weekly Report · 2021 · 794 citations
- Medicine
- Virology
- Immunology
In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. Estimated mRNA vaccine effectiveness for prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.
Frequent coauthors
- 490 shared
David Lee
University of Miami
- 326 shared
Natasha Schaefer Solle
- 257 shared
Lora E. Fleming
University of Exeter
- 231 shared
Erin N. Kobetz
University of Miami
- 199 shared
Paola Louzado‐Feliciano
University of Miami
- 188 shared
William G. LeBlanc
University of Colorado Denver
- 180 shared
Katerina M. Santiago
University of Miami
- 179 shared
Sharon L. Christ
Google (United States)
Education
- 2013
Postdoctoral Fellowship, Environmental Health
Harvard School of Public Health
- 2011
PhD / Epidemiology, Epidemiology & Public Health
University of Miami Miller School of Medicine
- 2011
DO / Osteopathic Medicine
Nova Southeastern University College of Osteopathic Medicine
- 2004
MPH / Public Health, Public Health
Nova Southeastern University College of Osteopathic Medicine
- 2001
BS / Computer Science, Computer Science
University of Miami
Similar researchers at University of North Carolina at Chapel Hill
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Amanda Marie Martínez
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup